Last reviewed · How we verify
Capecitabine combined with Pyrotinib
Capecitabine combined with Pyrotinib is a Combination chemotherapy and tyrosine kinase inhibitor Small molecule drug developed by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. It is currently in Phase 3 development for HER2-positive metastatic breast cancer, HER2-positive gastric cancer. Also known as: xeloda combined with Pyrotinib.
Capecitabine is a prodrug that converts to 5-fluorouracil to inhibit thymidylate synthase, while pyrotinib is a pan-HER tyrosine kinase inhibitor that blocks HER1, HER2, and HER4 signaling.
Capecitabine is a prodrug that converts to 5-fluorouracil to inhibit thymidylate synthase, while pyrotinib is a pan-HER tyrosine kinase inhibitor that blocks HER1, HER2, and HER4 signaling. Used for HER2-positive metastatic breast cancer, HER2-positive gastric cancer.
At a glance
| Generic name | Capecitabine combined with Pyrotinib |
|---|---|
| Also known as | xeloda combined with Pyrotinib |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Drug class | Combination chemotherapy and tyrosine kinase inhibitor |
| Target | Thymidylate synthase (capecitabine); HER1/EGFR, HER2, HER4 (pyrotinib) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This combination targets cancer cells through dual mechanisms: capecitabine disrupts DNA synthesis by inhibiting thymidylate synthase, while pyrotinib irreversibly inhibits multiple HER family receptor tyrosine kinases. Together, they provide complementary cytotoxic and targeted inhibition of HER-driven proliferation pathways, particularly effective in HER2-positive cancers.
Approved indications
- HER2-positive metastatic breast cancer
- HER2-positive gastric cancer
Common side effects
- Hand-foot skin reaction
- Diarrhea
- Nausea and vomiting
- Fatigue
- Rash
- Myelosuppression
Key clinical trials
- A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane (PHASE3)
- A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors (PHASE1, PHASE2)
- A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors (PHASE2)
- Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer (PHASE2)
- Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC
- Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer (PHASE2)
- RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody
- The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Capecitabine combined with Pyrotinib CI brief — competitive landscape report
- Capecitabine combined with Pyrotinib updates RSS · CI watch RSS
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University portfolio CI
Frequently asked questions about Capecitabine combined with Pyrotinib
What is Capecitabine combined with Pyrotinib?
How does Capecitabine combined with Pyrotinib work?
What is Capecitabine combined with Pyrotinib used for?
Who makes Capecitabine combined with Pyrotinib?
Is Capecitabine combined with Pyrotinib also known as anything else?
What drug class is Capecitabine combined with Pyrotinib in?
What development phase is Capecitabine combined with Pyrotinib in?
What are the side effects of Capecitabine combined with Pyrotinib?
What does Capecitabine combined with Pyrotinib target?
Related
- Drug class: All Combination chemotherapy and tyrosine kinase inhibitor drugs
- Target: All drugs targeting Thymidylate synthase (capecitabine); HER1/EGFR, HER2, HER4 (pyrotinib)
- Manufacturer: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for HER2-positive metastatic breast cancer
- Indication: Drugs for HER2-positive gastric cancer
- Also known as: xeloda combined with Pyrotinib
- Compare: Capecitabine combined with Pyrotinib vs similar drugs
- Pricing: Capecitabine combined with Pyrotinib cost, discount & access